Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSG-01 for Chronic Heart Failure
NCT04515290Phase 2Completed
- Sponsor
- Shanghai Hongyitang Biopharmaceutical Technology
- Start
- May 2020
- Primary completion
- Apr 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TSG-01 in chronic heart failure (CHF), sponsored by Shanghai Hongyitang Biopharmaceutical Technology. Started May 2020; status: completed.
02
Drugs
TSG-01
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT04515290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515290.